{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:12:42Z","timestamp":1789776762248,"version":"4.0.1"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T00:00:00Z","timestamp":1675382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018543","name":"Natural Science Foundation of Tibet Autonomous Region","doi-asserted-by":"publisher","award":["XZ2021ZR-ZY09(Z)"],"award-info":[{"award-number":["XZ2021ZR-ZY09(Z)"]}],"id":[{"id":"10.13039\/501100018543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Backgrounds<\/jats:title><jats:p>Despite the genomic landscape of urothelial carcinomas (UC) patients, especially those with UC of bladder (UCB), has been comprehensively delineated and associated with pathogenetic mechanisms and treatment preferences, the genomic characterization of upper tract UC (UTUC) has yet to be fully elucidated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>A total of 131 Chinese UTUC (74 renal pelvis &amp;amp; 57 ureter) and 118 UCB patients were enrolled in the present study, and targeted next-generation sequencing (NGS) of 618 cancer-associated genes were conducted to exhibit the profile of somatic and germline alterations. The COSMIC database, including 30 mutational signatures, were utilized to evaluate the mutational spectrums. Moreover, TCGA-UCB, MSKCC-UCB, and MSKCC-UTUC datasets were retrieved for preforming genomic alterations (GAs) comparison analysis between Western and Chinese UC patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In our cohort, 93.98% and 56.63% of UC patients were identified with oncogenic and actionable somatic alterations, respectively. Meanwhile, 11.24% of Chinese UC patients (of 14.50% and 7.63% of UTUC and UCB cases, respectively) were identified to harbor a total of 32 pathogenic\/likely-pathogenic germline variants in 22 genes, with DNA damage repair (DDR)-associated <jats:italic>BRCA1<\/jats:italic> (1.20%) and <jats:italic>CHEK2<\/jats:italic> (1.20%) being the most prevalent. Chinese UTUC and UCB patients possessed distinct somatic genomic characteristics, especially with significantly different prevalence in <jats:italic>KMT2D\/C\/A<\/jats:italic>, <jats:italic>GNAQ<\/jats:italic>, <jats:italic>ERCC2<\/jats:italic>, <jats:italic>RB1<\/jats:italic>, and <jats:italic>PPM1D<\/jats:italic>. In addition, we also found notable differences in the prevalence of <jats:italic>ELF3<\/jats:italic>, <jats:italic>TP53<\/jats:italic>, <jats:italic>PMS2<\/jats:italic>, and <jats:italic>FAT4<\/jats:italic> between renal pelvis and ureter carcinomas. Moreover, 22.90% and 33.90% of UTUC and UCB patients, respectively, had at least one deleterious\/likely deleterious alteration in DDR related genes\/pathways. Subsequently, mutational signature analysis revealed that UC patients with mutational signature 22, irrespective of UTUC or UCB, consistently had the markedly higher level of tumor mutational burden (TMB), which was proved to be positively correlated with the objective complete\/partial response rate in the IMvigor210 cohort. By comparison, Chinese and Western UTUC patients also differed regrading GAs in oncogenic-related genes\/pathways, especially in TP53, RTK\/RAS, and PI3K pathways; besides, more alterations in WNT pathway but less TP53, RTK\/RAS, HIPPO, and PI3K pathways were identified in Chinese UCB.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussions<\/jats:title><jats:p>The in-depth analysis of genomic mutational landscapes revealed distinct pathogenetic mechanisms between Chinese UTUC and UCB, and specific genomic characterizations could identify high risk population of UTUC\/UCB and provided information regarding the selection of alternative therapeutic regimens.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.1097730","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T06:46:32Z","timestamp":1675406792000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy &amp; immunotherapy"],"prefix":"10.3389","volume":"13","author":[{"given":"Qi","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengwei","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunru","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changwei","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiangqiang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuesong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","article-title":"Bladder cancer incidence and mortality: A global overview and recent trends","volume":"71","author":"Antoni","year":"2017","journal-title":"Eur Urol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: A Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2022.02.002","article-title":"Cancer incidence and mortality in China, 2016","author":"Zheng","year":"2022","journal-title":"J Natl Cancer Center"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.05.079","article-title":"Urothelial carcinoma of the bladder and the upper tract: disparate twins","volume":"189","author":"Green","year":"2013","journal-title":"J Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.4581","article-title":"Comprehensive genomic profiling (CGP) of upper-tract (UTUC) and bladder (BUC) urothelial carcinoma reveals opportunities for therapeutic and biomarker development","volume":"37","author":"Necchi","year":"2019","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2017.11","article-title":"The evolving genomic landscape of urothelial carcinoma","volume":"14","author":"Glaser","year":"2017","journal-title":"Nat Rev Urol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"Weinstein","year":"2014","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2039","article-title":"Clonal relatedness and mutational differences between upper tract and bladder urothelial carcinoma","volume":"25","author":"Audenet","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2020.08.001","article-title":"Comprehensive genomic profiling of upper-tract and bladder urothelial carcinoma","volume":"7","author":"Necchi","year":"2021","journal-title":"Eur Urol Focus"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3147","article-title":"Mutational analysis of 472 urothelial carcinoma across grades and anatomic sites","volume":"25","author":"Nassar","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2520","article-title":"DNA Damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma","volume":"23","author":"Teo","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.7740","article-title":"Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1\/PD-L1 blockade in advanced urothelial cancers","volume":"36","author":"Teo","year":"2018","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.08838.x","article-title":"Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract","volume":"104","author":"Colin","year":"2009","journal-title":"BJU Int"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0701248104","article-title":"Aristolochic acid and the etiology of endemic (Balkan) nephropathy","volume":"104","author":"Grollman","year":"2007","journal-title":"Proc Natl Acad Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2013.04.001","article-title":"Prevalence and factors associated with baseline chronic kidney disease in China: A 10-year study of 785 upper urinary tract urothelial carcinoma patients","volume":"113","author":"Xiong","year":"2014","journal-title":"J Formosan Med Assoc"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.12.102","article-title":"Upper urinary tract carcinoma in lynch syndrome cases","volume":"185","author":"Crockett","year":"2011","journal-title":"J Urol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.0820","article-title":"Analysis of EPCAM protein expression in diagnostics of lynch syndrome","volume":"29","author":"Kloor","year":"2011","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in the cancer genome atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.4_suppl.309","article-title":"Targeted sequencing of upper tract urothelial carcinoma","volume":"32","author":"Sfakianos","year":"2014","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","article-title":"An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics","volume":"173","author":"Liu","year":"2018","journal-title":"Cell"},{"key":"B22","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.eururo.2014.06.050","article-title":"Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder","volume":"67","author":"Kim","year":"2015","journal-title":"Eur Urol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nrc3816","article-title":"Hypermutation in human cancer genomes: footprints and mechanisms","volume":"14","author":"Roberts","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.05.048","article-title":"Comprehensive genomic characterization of upper tract urothelial carcinoma","volume":"72","author":"Moss","year":"2017","journal-title":"Eur Urol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"515.e511","DOI":"10.1016\/j.urology.2009.11.046","article-title":"Quantitative loss of heterozygosity analysis for urothelial carcinoma detection and prognosis","volume":"76","author":"Collin-Chavagnac","year":"2010","journal-title":"Urology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01395","article-title":"Cancer susceptibility mutations in patients with urothelial malignancies","volume":"38","author":"Carlo","year":"2020","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2016.171","article-title":"Upper tract urothelial carcinomas: frequency of association with mismatch repair protein loss and lynch syndrome","volume":"30","author":"Harper","year":"2017","journal-title":"Modern Pathol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00283","article-title":"Microsatellite instability is associated with the presence of lynch syndrome pan-cancer","volume":"37","author":"Latham","year":"2019","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2015.08.018","article-title":"Urinary tract cancer in lynch syndrome; increased risk in carriers of MSH2 mutations","volume":"86","author":"Joost","year":"2015","journal-title":"Urology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.774202","article-title":"Identification of germline mutations in upper tract urothelial carcinoma with suspected lynch syndrome","volume":"12","author":"Guan","year":"2022","journal-title":"Front Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-019-0720-x","article-title":"Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma","volume":"22","author":"Nassar","year":"2020","journal-title":"Genet Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0257","article-title":"Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and prognostic importance of DNA repair gene mutations on survival","volume":"20","author":"Yap","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.1056","article-title":"Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma","volume":"2","author":"Liu","year":"2016","journal-title":"JAMA Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"New Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12885-021-07829-1","article-title":"Genomic profiling of Chinese patients with urothelial carcinoma","volume":"21","author":"Yang","year":"2021","journal-title":"BMC Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2017.10.021","article-title":"Human RecQL4 helicase plays multifaceted roles in the genomic stability of normal and cancer cells","volume":"413","author":"Mo","year":"2018","journal-title":"Cancer Lett"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-004-7993-0","article-title":"Lynch syndrome genes","volume":"4","author":"Peltom\u00e4ki","year":"2005","journal-title":"Familial Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01388","article-title":"Harnessing DNA double-strand break repair for cancer treatment","volume":"9","author":"Trenner","year":"2019","journal-title":"Front Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"JCO.22.00205","DOI":"10.1200\/jco.22.00205","article-title":"Durvalumab plus olaparib in previously untreated, platinum-ineligible patients with metastatic urothelial carcinoma: A multicenter, randomized, phase II trial (BAYOU)","author":"Rosenberg","year":"","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s41591-021-01317-6","article-title":"An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer","volume":"27","author":"Powles","year":"2021","journal-title":"Nat Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.721030","article-title":"Pan-cancer analysis of PARP1 alterations as biomarkers in the prediction of immunotherapeutic effects and the association of its expression levels and immunotherapy signatures","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-2652","article-title":"Development of PARP and immune-checkpoint inhibitor combinations","volume":"78","author":"Stewart","year":"2018","journal-title":"Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s40425-019-0619-8","article-title":"DNA Damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes","volume":"7","author":"Vidotto","year":"2019","journal-title":"J ImmunoTherapy Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra072067","article-title":"Epigenetics in cancer","volume":"358","author":"Esteller","year":"2008","journal-title":"New Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-020-00386-5","article-title":"The complex genetics of epigenetics in urothelial carcinomas","volume":"17","author":"Frew","year":"2020","journal-title":"Nat Rev Urol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13839","article-title":"Comparison of genomic characterization in upper tract urothelial carcinoma and urothelial carcinoma of the bladder","volume":"26","author":"Yang","year":"2021","journal-title":"Oncologist"},{"key":"B49","doi-asserted-by":"publisher","first-page":"104567","DOI":"10.1016\/j.phrs.2019.104567","article-title":"The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder","volume":"151","author":"Roskoski","year":"2020","journal-title":"Pharmacol Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0274","article-title":"Molecular drivers of the non-T-cell-Inflamed tumor microenvironment in urothelial bladder cancer","volume":"4","author":"Sweis","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"B52","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.eururo.2019.06.025","article-title":"Fibroblast growth factor receptor 3 alterations and response to PD-1\/PD-L1 blockade in patients with metastatic urothelial cancer","volume":"76","author":"Wang","year":"2019","journal-title":"Eur Urol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.07.018","article-title":"Fibroblast growth factor receptor 3 alteration status is associated with differential sensitivity to platinum-based chemotherapy in locally advanced and metastatic urothelial carcinoma","volume":"78","author":"Teo","year":"2020","journal-title":"Eur Urol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.07.002","article-title":"FGFR3 mutation status and FGFR3 expression in a Large bladder cancer cohort treated by radical cystectomy: Implications for anti-FGFR3 treatment?\u2020","volume":"78","author":"van Rhijn","year":"2020","journal-title":"Eur Urol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.ctrv.2015.06.004","article-title":"Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma","volume":"41","author":"Ikeda","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"B56","doi-asserted-by":"publisher","first-page":"109956","DOI":"10.1016\/j.biopha.2020.109956","article-title":"The role of PPM1D in cancer and advances in studies of its inhibitors","volume":"125","author":"Deng","year":"2020","journal-title":"Biomedicine Pharmacotherapy"},{"key":"B57","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.eururo.2015.02.034","article-title":"Consequences of disrupted notch signaling in bladder cancer","volume":"68","author":"Greife","year":"2015","journal-title":"Eur Urol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.6_suppl.392","article-title":"Socio-environmental conditions associated with geospatial clusters of urothelial carcinoma: A multi-institutional analysis","volume":"39","author":"Edwards","year":"2021","journal-title":"J Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13073-015-0161-3","article-title":"Mutation signatures implicate aristolochic acid in bladder cancer development","volume":"7","author":"Poon","year":"2015","journal-title":"Genome Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.6_suppl.494","article-title":"Tumor mutation burden and immune microenvironment analysis of urothelial carcinoma","volume":"39","author":"Jia","year":"2021","journal-title":"J Clin Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.7_suppl.438","article-title":"Alterations of DNA damage response (DDR) genes correlate with favorable response and overall survival (OS) in anti-PD-1\/PD-L1-treated advanced urothelial cancer (UC)","volume":"37","author":"Joshi","year":"2019","journal-title":"J Clin Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-0977","article-title":"Genomic predictors of good outcome, recurrence, or progression in high-grade T1 non\u2013Muscle-Invasive bladder cancer","volume":"80","author":"Bellmunt","year":"2020","journal-title":"Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"465","DOI":"10.21037\/atm-21-289","article-title":"Comprehensive analyses of PBRM1 in multiple cancer types and its association with clinical response to immunotherapy and immune infiltrates","volume":"9","author":"Yang","year":"2021","journal-title":"Ann Trans Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2210","article-title":"Safety, efficacy, and biomarker analysis of toripalimab in patients with previously treated advanced urothelial carcinoma: Results from a multicenter phase II trial POLARIS-03","volume":"28","author":"Sheng","year":"2022","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1097730\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T06:46:37Z","timestamp":1675406797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1097730\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,3]]},"references-count":65,"alternative-id":["10.3389\/fimmu.2022.1097730"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1097730","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,3]]},"article-number":"1097730"}}